Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TGRX 326

Next Previous
Drug Profile

TGRX 326

Alternative Names: TGRX-326

Latest Information Update: 09 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen TargetRx
  • Developer Shenzhen TargetRx; Sun Yat-Sen University Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 02 Sep 2024 TGRX 326 licensed to Simcere Zaiming in Mainland China
  • 21 Jul 2024 Shenzhen TargetRx completes a phase I pharmacokinetics trial (In Volunteers) in China (PO) (NCT06438367)
  • 26 Jun 2024 Shenzhen TargetRx initiates a phase I pharmacokinetics trial (In Volunteers) in China (PO) (NCT06438367)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top